A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Amneal Pharmaceuticals, Inc.
AMRX
$5.9B
Mkt Cap
$17.92
-0.28%
Amneal Pharmaceuticals, Inc. (AMRX) has a current P/E ratio of 81.5, compared to its historical median P/E of 58.9. The stock is currently considered Fair based on its historical valuation range.
Amneal Pharmaceuticals, Inc. (AMRX) has a 5-year average return on invested capital (ROIC) of 6.9%. This is below average and may indicate limited pricing power.
Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $5.9B. It is classified as a mid-cap stock.
Amneal Pharmaceuticals, Inc. (AMRX) does not currently pay a regular dividend.
Based on historical P/E analysis, Amneal Pharmaceuticals, Inc. (AMRX) appears fair. The current P/E of 81.5 is 38% above its historical median of 58.9. The estimated fair value CAGR (P/E method) is -36.4%.
Amneal Pharmaceuticals, Inc. (AMRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Amneal Pharmaceuticals, Inc. (AMRX) reported annual revenue of $3.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and Ireland. Refer to the section “Segments of the Business” below for an overview of our segments. Corporate Structure We are a holding company, whose principal assets are common units (the “Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”). Immediately prior to the Reorganization (as defined herein), we held 50.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.0B | 3.0B | 2.8B | 2.4B | 2.2B | 2.1B |
| Net Income | 122M | 72M | -117M | -84M | -130M | 11M |
| EPS | $0.37 | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Free Cash Flow | 241M | 270M | 243M | 302M | 19M | 194M |
| ROIC | 18.6% | 16.5% | 11.0% | 7.8% | -4.4% | 3.5% |
| Gross Margin | 38.7% | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% |
| Debt/Equity | 0.00 | -36.33 | -21.84 | 122.35 | 8.79 | 7.52 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 436M | 394M | 249M | 204M | -95M | 153M |
| Operating Margin | 14.3% | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% |
| ROE | 0.0% | -80.0% | 261.2% | -52.8% | -39.5% | 3.2% |
| Shares Outstanding | 329M | 328M | 308M | 175M | 151M | 152M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.0B | 1.0B | 1.7B | 1.6B | 2.0B | 2.1B | 2.2B | 2.4B | 2.8B | 3.0B | 3.0B |
| Gross Margin | 58.7% | 50.9% | 43.1% | 21.7% | 31.5% | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% | 38.7% |
| R&D | 179M | 171M | 194M | 188M | 180M | 202M | 196M | 164M | 191M | 186M | 185M |
| SG&A | 119M | 109M | 228M | 290M | 327M | 366M | 400M | 430M | 476M | 527M | 547M |
| EBIT | 285M | 245M | -20M | -249M | 91M | 153M | -95M | 204M | 249M | 394M | 436M |
| Op. Margin | 28.0% | 23.7% | -1.2% | -15.3% | 4.6% | 7.3% | -4.3% | 8.5% | 8.9% | 13.1% | 14.3% |
| Net Income | N/A | N/A | -21M | -362M | 91M | 11M | -130M | -84M | -117M | 72M | 122M |
| Net Margin | N/A | N/A | -1.3% | -22.3% | 4.6% | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% | 4.0% |
| Non-Recurring | 0 | 3.9M | 56M | 40M | 2.4M | 2.6M | 14M | 1.7M | 2.4M | 4.2M | 4.3M |
| Returns on Capital | |||||||||||
| ROIC | N/A | N/A | -0.9% | -12.1% | 3.3% | 3.5% | -4.4% | 7.8% | 11.0% | 16.5% | 18.6% |
| ROE | N/A | N/A | -4.1% | -98.2% | 34.0% | 3.2% | -39.5% | -52.8% | 261.2% | -80.0% | 0.0% |
| ROA | N/A | N/A | -0.7% | -9.0% | 2.4% | 0.3% | -3.4% | -2.3% | -3.4% | 2.0% | 3.4% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 115M | 234M | 250M | 1.7M | 379M | 242M | 65M | 346M | 295M | 340M | 306M |
| Free Cash Flow | -7.7M | 139M | 167M | -45M | 323M | 194M | 19M | 302M | 243M | 270M | 241M |
| Owner Earnings | 82M | 119M | -126M | -227M | 123M | -20M | -207M | 89M | 31M | 84M | -319M |
| CapEx | 123M | 95M | 83M | 47M | 56M | 48M | 46M | 43M | 52M | 70M | 65M |
| Maint. CapEx | 33M | 115M | 208M | 207M | 235M | 233M | 240M | 229M | 236M | 224M | 591M |
| Growth CapEx | 90M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 33M | 115M | 208M | 207M | 235M | 233M | 240M | 229M | 236M | 224M | 591M |
| CapEx/OCF | N/A | N/A | 33.2% | 2767.2% | 14.9% | 19.7% | 71.3% | 12.5% | 17.6% | 20.6% | 21.3% |
| Capital Allocation | |||||||||||
| Dividends Paid | 201M | 375M | 183M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | 7.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 0 | 0 | 168M | 22M | 21M | 28M | 32M | 27M | 28M | 32M | 34M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 1.7M | 162M | 71K | 75M | 75M |
| Balance Sheet | |||||||||||
| Net Debt | N/A | 1.4B | 2.4B | 2.5B | 2.4B | 2.5B | 2.6B | 2.3B | 2.3B | 2.3B | 2.4B |
| Cash & Equiv. | 27M | 74M | 213M | 151M | 341M | 248M | 26M | 92M | 111M | 282M | 198M |
| Long-Term Debt | N/A | 1.4B | 2.6B | 2.6B | 2.7B | 2.7B | 2.6B | 2.4B | 2.2B | 2.6B | 2.6B |
| Debt/Equity | N/A | N/A | 5.25 | 11.34 | 9.17 | 7.52 | 8.79 | 122.35 | -21.84 | -36.33 | 0.00 |
| Interest Coverage | 5.6 | 28.1 | -0.6 | -53.6 | 19.1 | 33.2 | -21.1 | 44.6 | 54.9 | 89.8 | 14.6 |
| Equity | 43K | 0 | 505M | 232M | 303M | 360M | 298M | 20M | -109M | -71M | -45M |
| Total Assets | N/A | 1.3B | 4.4B | 3.7B | 4.0B | 3.9B | 3.8B | 3.5B | 3.5B | 3.7B | 3.5B |
| Total Liabilities | N/A | 1.3B | 3.5B | 3.3B | 3.7B | 3.6B | 3.6B | 3.5B | 3.6B | 3.7B | -125M |
| Intangibles | N/A | 45M | 1.7B | 1.4B | 1.3B | 1.2B | 1.1B | 890M | 732M | 563M | 535M |
| Retained Earnings | N/A | -383M | -21M | -378M | -287M | -276M | -406M | -490M | -607M | -535M | -473M |
| Working Capital | N/A | 475M | 733M | 660M | 875M | 843M | 659M | 531M | 458M | 1.0B | 1.1B |
| Current Assets | N/A | 772M | 1.3B | 1.2B | 1.6B | 1.5B | 1.4B | 1.4B | 1.6B | 1.9B | 1.8B |
| Current Liabilities | N/A | 297M | 554M | 550M | 677M | 677M | 753M | 847M | 1.1B | 882M | 728M |
| Per Share Data | |||||||||||
| EPS | N/A | N/A | -0.16 | -2.74 | 0.61 | 0.07 | -0.86 | -0.48 | -0.38 | 0.22 | 0.37 |
| Owner EPS | N/A | 119,239.00 | -0.96 | -1.72 | 0.82 | -0.13 | -1.37 | 0.51 | 0.10 | 0.26 | -0.97 |
| Book Value | N/A | 0.00 | 3.86 | 1.76 | 2.03 | 2.37 | 1.97 | 0.11 | -0.36 | -0.22 | -0.14 |
| Cash Flow/Share | N/A | 234,187.00 | 1.91 | 0.01 | 2.54 | 1.59 | 0.43 | 1.97 | 0.96 | 1.04 | 2.17 |
| Dividends/Share | N/A | 375,265.00 | 1.40 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 0.0M | 130.8M | 132.1M | 149.3M | 151.8M | 151.1M | 175.0M | 307.6M | 327.5M | 328.9M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 7.3 | 71.7 | N/A | N/A | N/A | 58.9 | 47.9 |
| P/FCF | N/A | N/A | 10.8 | N/A | 2.1 | 3.9 | 15.9 | 3.5 | 9.9 | 15.7 | 24.5 |
| EV/EBIT | N/A | N/A | N/A | N/A | 38.3 | 24.5 | N/A | 17.1 | 18.7 | 15.9 | 19.0 |
| Price/Book | N/A | N/A | 8.2 | 5.8 | 4.5 | 4.2 | 2.0 | 54.1 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 3.4 | 1.4 | 0.6 | 0.8 | 0.5 | 0.2 | 0.8 | 1.0 | 1.9 |
| FCF Yield | N/A | N/A | 4.0% | -3.4% | 23.9% | 12.7% | 3.1% | 28.2% | 10.1% | 6.4% | 4.1% |
| Market Cap | 0 | N/A | 4.1B | 1.4B | 1.4B | 1.5B | 605M | 1.1B | 2.4B | 4.2B | 5.9B |
| Avg. Price | 0.00 | N/A | 19.10 | 7.60 | 4.27 | 5.30 | 3.30 | 3.06 | 7.06 | 9.05 | 17.92 |
| Year-End Price | 0.00 | N/A | 13.85 | 4.51 | 4.48 | 5.02 | 1.97 | 6.12 | 7.82 | 12.95 | 17.92 |
Amneal Pharmaceuticals, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Amneal Pharmaceuticals, Inc. trades at 81.5x trailing earnings, compared to its 15-year median P/E of 58.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 20.9x vs a median of 9.9x. The company's 5-year average ROIC is 6.9% with a gross margin of 36.0%. At current prices, the estimated annualized return to fair value is +11.5%.
Amneal Pharmaceuticals, Inc. (AMRX) has a net profit margin of 2.4%. This is a modest margin.
Amneal Pharmaceuticals, Inc. (AMRX) generated $270 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Amneal Pharmaceuticals, Inc. (AMRX) reported earnings per share (EPS) of $0.22 in its most recent fiscal year.
Amneal Pharmaceuticals, Inc. (AMRX) has a return on equity (ROE) of -80.0%. A negative ROE may indicate losses or negative equity.
Amneal Pharmaceuticals, Inc. (AMRX) has a 5-year average gross margin of 36.0%. This indicates decent pricing power.
The Ledger Terminal provides 10 years of financial data for Amneal Pharmaceuticals, Inc. (AMRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Amneal Pharmaceuticals, Inc. (AMRX) has a book value per share of $-0.22, based on its most recent annual SEC filing.